Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dreaming01:30

Dreaming

142
Sigmund Freud revolutionized our understanding of dreams by proposing that they are a window into the unconscious mind. According to Freud, dreams are not mere stories our minds create while we sleep but are profoundly meaningful narratives about our hidden desires and fears. He introduced two key concepts: manifest content and latent content. The manifest content is the actual content and imagery of the dream — what we remember when we wake up. The latent content, however, represents the...
142
Lucid Dreaming01:10

Lucid Dreaming

125
Lucid dreaming is a unique state of consciousness where an individual realizes they are dreaming while still in the dream. This awareness allows them to manipulate their dream environment consciously. Researchers like Stephen LaBerge have significantly contributed to the understanding of lucid dreams, highlighting that during these dreams, certain areas of the brain, such as the prefrontal cortex, that involve self-awareness and thought evaluation show increased activity.
Studies have shown...
125
Self-Discrepancy Theory02:45

Self-Discrepancy Theory

18.3K
One influential perspective on what motivates people's behavior is detailed in Tory Higgin's self-discrepancy theory (Higgins, 1987). He proposed that people hold disagreeing internal representations of themselves that lead to different emotional states.  
18.3K
Repressed Memory01:16

Repressed Memory

71
Repressed memories are a psychological phenomenon where memories of traumatic events are unconsciously blocked from a person's awareness. This process occurs as a defense mechanism, protecting the mind from the emotional impact of distressing or painful experiences. For example, a person who has experienced childhood trauma may grow up with no conscious recollection of the event. In such cases, the memories are thought to be buried deep within the subconscious, inaccessible to the conscious...
71
Coping Strategies: Problem Focused01:27

Coping Strategies: Problem Focused

51
Coping strategies are methods people use to manage, tolerate, or reduce the effects of stressors. These strategies involve both behavioral and psychological actions to handle stressful situations. One common approach is problem-focused coping, which aims to change or eliminate the source of stress rather than merely addressing its consequences. This method involves taking direct action to resolve the issue causing stress.
For example, consider a student who struggles to understand their...
51
Nightmares and Night Terrors01:18

Nightmares and Night Terrors

80
Nightmares and night terrors represent two distinct types of sleep disturbances that differ in timing, characteristics, and the sleeper's recall of the event. Nightmares are vivid, disturbing dreams that usually awaken the sleeper from REM sleep, a stage of sleep where brain activity is high, and dreams are most frequent. Upon awakening, individuals often have detailed recollections of their nightmares, which can include themes of threats to survival, security, or self-esteem.
Nightmares...
80

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same author

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.

bioRxiv : the preprint server for biology·2026
Same author

The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026
Same author

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.

Blood cancer discovery·2025
Same journal

Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.

Med (New York, N.Y.)·2026
Same journal

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Med (New York, N.Y.)·2026
Same journal

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026
Same journal

Atlas of human brain imaging-derived phenotypes and disease risk.

Med (New York, N.Y.)·2026
Same journal

Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine.

Med (New York, N.Y.)·2026
Same journal

Rethinking parenteral nutrition as supportive therapy for neonatal sepsis.

Med (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Task Interruption and Resumption Paradigm for Testing the Activation and Pursuit of an Abstract Thinking Goal
06:45

Task Interruption and Resumption Paradigm for Testing the Activation and Pursuit of an Abstract Thinking Goal

Published on: April 18, 2017

6.2K

How to rescue a DreaMM deferred ….

Nisha S Joseph1, Sagar Lonial1

  • 1Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Med (New York, N.Y.)
|September 14, 2024
PubMed
Summary
This summary is machine-generated.

The DreaMM-7 and -8 trials show that triplet regimens with belantamab mafodotin benefit patients with relapsed multiple myeloma. This analysis details efficacy and safety, informing future treatment strategies.

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.7K
Embryo Rescue Protocol for Interspecific Hybridization in Squash
09:15

Embryo Rescue Protocol for Interspecific Hybridization in Squash

Published on: September 12, 2022

2.6K

Related Experiment Videos

Last Updated: Jun 13, 2025

Task Interruption and Resumption Paradigm for Testing the Activation and Pursuit of an Abstract Thinking Goal
06:45

Task Interruption and Resumption Paradigm for Testing the Activation and Pursuit of an Abstract Thinking Goal

Published on: April 18, 2017

6.2K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.7K
Embryo Rescue Protocol for Interspecific Hybridization in Squash
09:15

Embryo Rescue Protocol for Interspecific Hybridization in Squash

Published on: September 12, 2022

2.6K

Area of Science:

  • Oncology
  • Hematology
  • Clinical Trials

Background:

  • Multiple myeloma is a hematologic malignancy.
  • Relapsed myeloma presents treatment challenges.
  • Anti-BCMA therapies are emerging.

Purpose of the Study:

  • To report findings from the DreaMM-7 and -8 trials.
  • To evaluate efficacy and safety of belantamab mafodotin combinations.
  • To discuss implications for relapsed myeloma treatment.

Main Methods:

  • Analysis of data from DreaMM-7 and -8 clinical trials.
  • Assessment of efficacy endpoints (e.g., response rates, survival).
  • Evaluation of safety profiles and adverse events.

Main Results:

  • Triplet regimens including belantamab mafodotin demonstrated clinical benefit.
  • Efficacy data supports the use of this combination.
  • Safety data provides insights into managing side effects.

Conclusions:

  • Belantamab mafodotin-containing triplets show promise in relapsed myeloma.
  • These findings impact future treatment paradigms.
  • Further research may refine its role in myeloma therapy.